While immune checkpoint inhibitor-based therapy did not provide benefits in clinical trials in CLL patients [38], some trials, including those with anti-BTLA monoclonal antibodies in hematological malignancies, are still ongoing (NCT04477772); however, no results have been published so far. The gene discussed is BTLA; the disease is B-cell chronic lymphocytic leukemia.